Advisory Committee Topics Will Narrow In Response To HRG Suit - FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA will ask more directed questions of its advisory committees as a way to narrow the amount of information from NDAs provided to the committees, FDA's Office of Training and Communications Director Nancy Smith, PhD, told the recent Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
You may also be interested in...
FDA Aims To Boost Transparency Through Earlier Release Of Panel Materials
FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a Feb. 28 draft guidance
FDA Aims To Boost Transparency Through Earlier Release Of Panel Materials
FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a Feb. 28 draft guidance
FDA Aims To Boost Transparency Through Earlier Release Of Panel Materials
FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a Feb. 28 draft guidance